Curcumin alleviates dystrophic muscle pathology in mdx mice

Molecules and Cells

Volumn 25, Issue 4, 2008, Pages 531-537

  Pan, Ying ^a,b   Chen, Chen ^a   Shen, Yue ^b   Zhu, Chun Hua ^c   Wang, Gang ^d   Wang, Xiao Chun ^b   Chen, Hua Qun ^c   Zhu, Min Sheng ^a  

^a NANJING UNIVERSITY   (China)

^b HUADONG RESEARCH INSTITUTE FOR MEDICINE AND BIOTECHNICS   (China)

^c NANJING NORMAL UNIVERSITY   (China)

^d CHILDREN S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Creatine kinase activity; Curcumin; i.p. injection; Interleukin 1beta; mdx Mice; Muscular dystrophy; NF B; Tumor necrosis factor alpha

Indexed keywords

CREATINE KINASE; CURCUMIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 10 MOUSE; CELL STRUCTURE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; ENZYME ACTIVITY; ENZYME INHIBITION; GEL MOBILITY SHIFT ASSAY; HISTOPATHOLOGY; MOUSE; MUSCLE FIBRIL; MUSCLE STRENGTH; NONHUMAN; SARCOLEMMA; WILD TYPE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CREATINE KINASE; CURCUMIN; HUMANS; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-1BETA; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; PHYTOTHERAPY; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 53949112196     PISSN: 10168478     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Acharyya, S., Villalta, S.A., Bakkar, N., Bupha-Intr, T., Janssen, P.M., Carathers, M., Li, Z.W., Beg, A.A., Ghosh, S., Sahenk, Z., et al. (2007). Interplay of IKK/NF-{kappa}B signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J. Clin. Invest. 117, 889-901.
2. Aggarwal, B.B., Kumar, A., and Bharti, A.C. (2003). Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 23, 363-398.
3. Ammon, H.P., and Wahl, M.A. (1991). Pharmacology of Curcuma longa. Planta Med. 57, 1-7.
4. Araujo, C.C., and Leon, L.L. (2001). Biological activities of Curcuma longa L. Mem. Inst. Oswaldo Cruz 96, 723-728.
5. Belzung, C., Guisquet, A.M., Barreau, S., and Calatayud, F. (2001). An investigation of the mechanisms responsible for acute fluoxetine-induced anxiogenic-like effects in mice. Behav. Pharmacol. 12, 151-162.
6. Blake, D.J., Tinsley, J.M., and Davies, K.E. (1996). Utrophin: a structural and functional comparison to dystrophin. Brain Pathol. 6, 37-47.
7. Cai, D., Frantz, J.D., Melendez, P.A., Oh, B.C., Lidov, H.G., Hasselgren, P.O., Frontera, W.R., Lee, J., Glass, D.J., and Shoelson, S.E. (2004). IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 119, 285-298.
8. Cammer, M., Minetti, C., and Lisanti, M.P. (2003). Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin associated proteins. Am. J. Pathol. 163, 1663-1675.
9. Das, K.C., and Das, C.K. (2002). Curcumin (diferuloylmethane), a singlet oxygen (102) quencher. Biochem. Biophys. Res. Commun. 95, 2-6.
10. Disatnik, M.H., Chamberlain, J.S., and Rando, T.A. (2000). Dystrophin mutations predict cellular susceptibility to oxidative stress. Muscle Nerve 23, 784-792.
11. Durham, W.J., Arbogast, S., Gerken, E., Li, Y.P., and Reid, M.B. (2006). Progressive nuclear factor-kB activation resistant to inhibition by contraction and curcumin in mdx mice. Muscle Nerve 34, 298-303.
12. Ghosh, S., May, M.J., and Kopp, E.B. (1998). NF-kappaB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 6, 25-60.
13. Griscavage, J.M., Hobbs, A.J., and Ignarro, L.J. (1995). Negative modulation of nitric oxide synthase by nitric oxide and nitroso compounds. Adv. Pharmacol. 34, 215-234.
14. Grounds, M.D., and Torrisi, J. (2004). Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J. 18, 676-682.
15. Hamed, S.A. (2006). Drug evaluation: PTC-124 - a potential treatment of cystic fibrosis and Duchenne muscular dystrophy. I. Drugs. 9, 783-789.
16. Hoffman, E.P., Brown, R.H. Jr., and Kunkel, L.M. (1987). Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919-928.
17. Hoffman, E.P., Fischbeck, K.H., Brown, R.H., Johnson, M., Medori, R., Loike, J.D., Harris, J.B., Waterston, R., Brooke, M., Specht, L., et al. (1988). Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N. Engl. J. Med. 318, 1363-1368.
18. Hunter, R.B., and Kandarian, S.C. (2004). Disruption of either the Nfkb1 or the Bcl3 gene inhibits skeletal muscle atrophy. J. Clin. Invest. 114, 1504-1511.
19. Koenig, M., Hoffman, E.P., Bertelson, C.J., Monaco, A.P., Feener, C., and Kunkel, L.M. (1987). Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50, 509-517.
20. Kumar, A., and Boriek, A.M. (2003). Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy. FASEB J. 17, 386-396.
21. Lapidos, K.A., Kakkar, R., and McNally, E.M. (2004). The dystrophin glycoprotein complex signaling strength and integrity for the sarcolemma. Circ. Res. 94, 1023-1031.
22. Louboutin, J.P., Rouger, K., Tinsley, J.M., Halldorson, J., and Wilson, J.M. (2001). iNOS expression in dystrophinopathies can be reduced by somatic gene transfer of dystrophin or utrophin. Mol. Med. 7, 355-364.
23. Lundberg, I., Brengman, J.M., and Engel, A.G. (1995). Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J. Neuroimmunol. 63, 9-16.
24. Mahmmoud, Y.A. (2005). Curcumin modulation of Na,K-ATPase: phosphoenzyme accumulation, decreased K+ occlusion, and inhibition of hydrolytic activity. Br. J. Pharmacol. 145, 236-245.
25. Matsumura, K., and Campbell, K.P. (1994). Dystrophin-glycoprotein complex: its role in the molecular pathogenesis of muscular dystrophies. Muscle Nerve 17, 2-15.
26. Meyer, O.A., Tilson, H.A., Byrd, W.C., and Riley, M.T. (1979). A method for the routine assessment of fore- and hindlimb grip strength of rats and mice. Neurobehav. Toxicol. 1, 233-236.
27. Monaco, A.P., Neve, R.L., Colletti-Feener, C., Bertelson, C.J., Kurnit, D.M., and Kunkel, L.M. (1986). Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 323, 646-650.
28. Murugesan, T., Saravanan, K.S., Lakshmi, S., and Ramya, G. (2001). Thenmozhi K: evaluation of psychopharmacological effects of clerodendrum phlomidis Linn. Extract Phytomedicine 8, 472-476.
29. Nowak, K.J., and Davies, K.E. (2004). Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep. 5, 872-876.
30. Oak, S.A., Zhou, Y.W., and Jarrett, H.W. (2003). Skeletal muscle signaling pathway through the dystrophin glycoprotein complex and Racl. J. Biol. Chem. 278, 39287-39295.
31. Pan, M.H., Lin-Shiau, S.Y., and Lin, J.K. (2000). Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through downregulation of IkappaB kinase and NFkappaB activation in macrophages. Biochem. Pharmacol. 60, 1665-1676.
32. Pasternak, C., Wong, S., and Elson, E.L. (1995). Mechanical function of dystrophin in muscle cells. J. Cell. Biol. 128, 355-361.
33. Rando, T.A., Disatnik, M.H., Yu, Y., and Franco, A. (1998). Muscle cells from mdx mice have an increased susceptibility to oxidative stress. Neuromuscul. Disord. 8, 14-21.
34. Sadoulet-Puccio, H.M. and Kunkel, L.M. (1996). Dystrophin and its isoforms. Brain Pathol. 6, 25-35.
35. Salvemini, D., and Marino, M.H. (1998). Inducible nitric oxide synthase and inflammation. Expert Opin. Investig. Drugs 7, 65-75.
36. Shishodia, S., Potdar, P., Gairola, C.G., and Aggarwal, B.B. (2003). Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-kappaB activation through inhibition of Ikappa-Balpha kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis 24, 1269-1279.
37. Spence, H.J., Dhillon, A.S., James, M., and Winder, S.J. (2004). Dystroglycan, a scaffold for the ERK-MAP kinase cascade. EMBO Rep. 5, 484-489.
38. St-Pierre, S.J., Chakkalakal, J.V., Kolodziejczyk, S.M., Knudson, J.C., Jasmin, B.J., and Megeney, L.A. (2004). Glucocorticoid treatment alleviates dystrophic myofiber pathology by activation of the calcineurin/NF-AT pathway. FASEB J. 18, 1937-1939.
39. Straub, V., Rafael, J.A., Chamberlain, J.S., and Campbell, K.P. (1997). Animal models for muscular dystrophy show different pattern of sarcolemmal disruption. J. Cell. Biol. 139, 375-385.
40. Tinsley, J.M., Blake, D.J., Zuellig, R.A., and Davies, K.E. (1994). Increasing complexity of the dystrophin-associated protein complex. Proc. Natl. Acad. Sci. USA 91, 8307-8313.
41. Villar, R., Laguna, M.R., Calleja, J.M., and Cadavid, I. (1992). Effects of Skeletonema costatum extracts on the central nervous system. Planta Med. 58, 398-403.
42. Yang, K.Y., Lin, L.C., Tseng, T.Y., Wang, S.C., and Tsai, T.H. (2007). Oral bioavailability of curcumin in rat and the herbal analysis from curcuma longa by LC-MS/MS. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 853, 183-189.
43. Zhu, M.S., Pan, Y., Chen, H.Q., Shen, Y., Wang, X.C., Sun, Y.J., and Tao, K.H. (2004). Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine. Immunol. Lett. 92, 237-243.